trending Market Intelligence /marketintelligence/en/news-insights/trending/c5kyeota__vyg3rxms7dlg2 content esgSubNav
In This List

Benitec Biopharma completes entitlement offer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Benitec Biopharma completes entitlement offer

Sydney-based Benitec Biopharma Ltd. said June 4 that it completed its previously announced entitlement offer.

The offer allowed existing shareholders to buy 1 new share of the company at 17 Australian cents each for every 2 existing shares held as of May 3.

A total of 36,442,672 new shares were issued under the entitlement offer. The shares are expected to commence trading on the Australian Securities Exchange on June 5.

Benitec develops and sells treatments for chronic and life-threatening illnesses using its gene-silencing therapy.